Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has a beta of 1.10, a 12-month trailing P/E ratio of 81.42, and a growth ratio of 5.82. The stock’s Relative Strength Index (RSI) is 56.32, with weekly volatility at 3.47% and ATR at 2.87. The HZNP stock’s 52-week price range has touched low of $48.98 and a $97.36 high. Its shares traded lower over the last trading session, losing -0.77% on 06/21/21. The shares fell to a low of $93.52 before closing at $93.88. Intraday shares traded counted 2.05 million, which was -21.22% lower than its 30-day average trading volume of 1.69M. HZNP’s previous close was $94.61 while the outstanding shares total 223.92M.
Investors have identified the Drug Manufacturers – General company Horizon Therapeutics Public Limited Company as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $20.55 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Horizon Therapeutics Public Limited Company (HZNP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For HZNP, the company has in raw cash 815.45 million on their books with 16.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. In terms of their assets, the company currently has 1.83 billion total, with 773.84 million as their total liabilities.
HZNP were able to record -22.06 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by -1.27 billion. In cash movements, the company had a total of -3.73 million as operating cash flow.
Potential earnings growth for Horizon Therapeutics Public Limited Company (HZNP)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, Horizon Therapeutics Public Limited Company recorded a total of 342.41 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -3.94% coming in sequential stages and their sales for the 08/11/2021 quarter reducing by -117.67%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 100.37 million trying to sell their products during the last quarter, with the result yielding a gross income of 242.04 million. This allows shareholders to hold on to 223.92M with the recently reported earning now reading -0.55 cents per share. This is a figure that compared to analyst’s prediction for their 08/11/2021 (0.03 cents a share).
Having a look at the company’s valuation, the company is expected to record 5.18 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on HZNP sounds very interesting.
Is the stock of HZNP attractive?
In related news, Chairman, President and CEO, Walbert Timothy P sold 25,000 shares of the company’s stock in a transaction that recorded on Jun 01. The sale was performed at an average price of 91.85, for a total value of 2,296,204. As the sale deal closes, the EVP, CFO, Hoelscher Paul W. now sold 102,925 shares of the company’s stock, valued at 9,263,847. Also, Director, Daniel William F sold 20,000 shares of the company’s stock in a deal that was recorded on May 10. The shares were price at an average price of 86.56 per share, with a total market value of 1,731,275. Following this completion of acquisition, the Chairman, President and CEO, Walbert Timothy P now holds 25,000 shares of the company’s stock, valued at 2,374,413. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.80%.
10 out of 11 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Horizon Therapeutics Public Limited Company. 0 analysts has assigned a Sell rating on the HZNP stock. The 12-month mean consensus price target for the company’s shares has been set at $114.18.